Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review

Figures & data

Table 1 Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

Authors	Country	Cases	Vaccines	Time	Dose
Temiz et al^Citation8	Turkey	31	BNT162b2: 14 AZD1222:17	Medium time: 12.7 days	First dose: 19 Second dose: 12
Freeman et al^Citation9	US	27	mRNA-1273: 16 BNT162b2: 8 AZD1222: 2 Ad26.COV2.S: 1	NR	First dose: 15 Second dose: 12
Català et al^Citation20	Spain	20	BNT162b2: 11 mRNA-1273: 5 AZD1222:4	Medium time: 6.3 days	First dose: 12 Second dose: 8
McMahon et al^Citation31	US	4	BNT162b2: 3 mRNA-1273: 1	Medium time: 7 days	First dose: 3 Second dose: 1
Martora et al^Citation33	Italy	3	mRNA-1273: 3	Medium time: 8 days	First dose: 3 Second dose: 0
Busto-Leis et al^Citation34	Spain	2	BNT162b2: 2	Medium time: 1–7 days	First dose: 1 Second dose: 1
Cyrenne et al^Citation35	Canada	2	BNT162b2: 2	Medium time: 4.5 days	First dose: 1 Second dose: 1
Farinazzo et al^Citation36	Italy	2	BNT162b2: 2	Medium time: 2–21 days	First dose: 1 Second dose: 1
Khattab et al^Citation37	Greece	2	BNT162b2: 2	Medium time: 7.5 days	First dose: 1 Second dose: 1
Abdullah et al^Citation38	Lebanon	1	BNT162b2: 1	7 days	First dose
Adya et al^Citation10	India	1	AZD1222:1	4 days	First dose
Bostan et al^Citation11	Turkey	1	BNT162b2: 1	15 days	Second dose
Buckley et al^Citation12	US	1	BNT162b2: 1	7 days	First dose
Burlando et al^Citation13	Italy	1	BNT162b2: 1	30 days	Second dose
Carballido Vázquez et al^Citation14	Spain	1	BNT162b2: 1	NR	First dose
Cohen et al^Citation15	US	1	BNT162b2: 1	7 days	First dose
Das et al^Citation16	India	1	AZD1222:1	NR	NR
Dormann et al^Citation17	Germany	1	AZD1222:1	12 days	First dose
Larson et al^Citation18	US	1	mRNA-1273: 1	7 days	Second dose
Leerunyakul et al^Citation19	Thailand	1	AZD1222:1	14 days	First dose
Marcantonio-Santa Cruz et al^Citation21	Spain	1	BNT162b2: 1	7 days	Second dose
Mehta et al^Citation22	India	1	AZD1222:1	1 days	First dose
Niebel et al^Citation23	Germany	1	AZD1222:1	21 days	First dose
Pedrazini et al^Citation24	Brazil	1	AZD1222:1	15 days	Second dose
Shin et al^Citation25	Korea	1	mRNA-1273: 1	3 days	Second dose
Tihy et al^Citation26	Switzerland	1	BNT162b2: 1	15 days	Second dose
Valk et al^Citation27	US	1	BNT162b2: 1	3 days	Second dose
Wang et al^Citation28	Taiwan	1	mRNA-1273: 1	7 days	First dose
Yu et al^Citation29	Philippines	1	AZD1222:1	3 days	First dose

Temiz SA, Abdelmaksoud A, Dursun R, Durmaz K, Sadoughifar R, Hasan A. Pityriasis rosea following SARS-CoV-2 vaccination: a case series. J Cosmet Dermatol. 2021;20(10):3080–3084. doi:10.1111/jocd.14372

 PubMed Web of Science ®Google Scholar

Freeman EE, Sun Q, McMahon DE, et al. Skin reactions to COVID-19 vaccines: an American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type. J Am Acad Dermatol. 2022;86(4):e165–e167. doi:10.1016/j.jaad.2021.11.016

 PubMed Web of Science ®Google Scholar

Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142–152. doi:10.1111/bjd.20639

 PubMed Web of Science ®Google Scholar

McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113–121. doi:10.1016/j.jaad.2021.09.002

 PubMed Web of Science ®Google Scholar

Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225

 PubMed Web of Science ®Google Scholar

Busto-Leis JM, Servera-Negre G, Mayor-Ibarguren A, et al. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. J Eur Acad Dermatol Venereol. 2021;35(8):e489–e491. doi:10.1111/jdv.17301

 PubMed Web of Science ®Google Scholar

Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. J Eur Acad Dermatol Venereol. 2021;35(9):e546–e548. doi:10.1111/jdv.17342

 Web of Science ®Google Scholar

Farinazzo E, Ponis G, Zelin E, et al. Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy. J Eur Acad Dermatol Venereol. 2021;35(9):e548–e551. doi:10.1111/jdv.17343

 Web of Science ®Google Scholar

Khattab E, Christaki E, Pitsios C. Pityriasis Rosea Induced by COVID-19 Vaccination. Eur J Case Rep Intern Med. 2022;9(2):3164. doi:10.12890/2022_003164

 Google Scholar

Abdullah L, Hasbani D, Kurban M, Abbas O. Pityriasis rosea after mRNA COVID-19 vaccination. Int J Dermatol. 2021;60(9):1150–1151. doi:10.1111/ijd.15700

 PubMed Web of Science ®Google Scholar

Adya KA, Inamadar AC, Albadri W. Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male. Dermatol Ther. 2021;34(5):e15040. doi:10.1111/dth.15040

 Web of Science ®Google Scholar

Bostan E, Jarbou A. Atypical pityriasis rosea associated with mRNA COVID-19 vaccine. J Med Virol. 2022;94(3):814–816. doi:10.1002/jmv.27364

 Web of Science ®Google Scholar

Buckley JE, Landis LN, Rapini RP. Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: a case report and review of the literature. JAAD Int. 2022;7:164–168. doi:10.1016/j.jdin.2022.01.009

 PubMedGoogle Scholar

Burlando M, Herzum A, Micalizzi C, Cozzani E, Parodi A. Cutaneous reactions to COVID-19 vaccine at the dermatology primary care. Immun Inflamm Dis. 2022;10(2):265–271. doi:10.1002/iid3.568

 PubMed Web of Science ®Google Scholar

Carballido Vázquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination. Br J Dermatol. 2021;185(2):e34. doi:10.1111/bjd.20143

 PubMed Web of Science ®Google Scholar

Cohen OG, Clark AK, Milbar H, Tarlow M. Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine. Hum Vaccin Immunother. 2021;17(11):4097–4098. doi:10.1080/21645515.2021.1963173

 PubMed Web of Science ®Google Scholar

Das P, Arora S, Singh GK, et al. A study of COVID-19 vaccine (Covishield) induced dermatological adverse effects from India. J Eur Acad Dermatol Venereol. 2022;36(6):e402–e404. doi:10.1111/jdv.17951

 Web of Science ®Google Scholar

Dormann H, Grummt S, Karg M. Pityriasis Rosea as a Possible Complication of Vaccination Against COVID-19. Dtsch Arztebl Int. 2021;118(25):431. doi:10.3238/arztebl.m2021.0257

 PubMedGoogle Scholar

Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2022;49(1):34–41. doi:10.1111/cup.14104

 Web of Science ®Google Scholar

Leerunyakul K, Pakornphadungsit K, Suchonwanit P. Case Report: pityriasis rosea-like eruption following COVID-19 vaccination. Front Med. 2021;8:752443. doi:10.3389/fmed.2021.752443

 Web of Science ®Google Scholar

Marcantonio-Santa Cruz OY, Vidal-Navarro A, Pesqué D, Giménez-Arnau AM, Pujol RM, Martin-Ezquerra G. Pityriasis rosea developing after COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e721–e722. doi:10.1111/jdv.17498

 Web of Science ®Google Scholar

Mehta H, Handa S, Malhotra P, et al. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India. J Eur Acad Dermatol Venereol. 2022;36(1):e16–e18. doi:10.1111/jdv.17678

 Web of Science ®Google Scholar

Niebel D, Wenzel J, Wilsmann-Theis D, Ziob J, Wilhelmi J, Braegelmann C. Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccines. Dermatopathol. 2021;8(4):463–476. doi:10.3390/dermatopathology8040049

 PubMed Web of Science ®Google Scholar

Pedrazini MC, Groppo FC. L-lysine therapy to control the clinical evolution of pityriasis rosea: clinical case report and literature review. Dermatol Ther. 2021;34(1):e14679. doi:10.1111/dth.14679

 Web of Science ®Google Scholar

Shin SH, Hong JK, Hong SA, Li K, Yoo KH. Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination. Int J Infect Dis IJID off Publ Int Soc Infect Dis. 2022;114:88–89. doi:10.1016/j.ijid.2021.10.055

 PubMed Web of Science ®Google Scholar

Tihy M, Menzinger S, André R, Laffitte E, Toutous-Trellu L, Kaya G. Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines. J Eur Acad Dermatol Venereol. 2021;35(12):2456–2461. doi:10.1111/jdv.17633

 Web of Science ®Google Scholar

Valk B, Bender B. Pityriasis rosea associated with COVID-19 vaccination: a common rash following administration of a novel vaccine. Cutis. 2021;108(6):317–318. doi:10.12788/cutis.0411

 PubMed Web of Science ®Google Scholar

Wang CS, Chen HH, Liu SH. Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: a case report and literature review. J Formos Med Assoc. 2022;121(5):1003–1007. doi:10.1016/j.jfma.2021.12.028

 PubMed Web of Science ®Google Scholar

Yu JN, Angeles CB, Lim HG, Chavez C, Roxas-Rosete C. Cutaneous reactions to inactivated SARS-CoV-2 vaccine and ChAdOx1-S (recombinant) vaccine against SARS-CoV-2: a case series from the Philippines. J Eur Acad Dermatol Venereol. 2021;35(12):e841–e845. doi:10.1111/jdv.17575

 Web of Science ®Google Scholar